Products
We provide access to modern, innovative biopharmaceuticals. Our products are developed by the world’s leading pharmaceutical experts and manufactured according to quality standards.
PRODUCT LINE
We have built a portfolio of high-quality, innovative drugs drawing on the knowledge and practices of the best Russian and global biotechnology companies and experts.
- Our portfolio includes products selected from among the world’s finest developments. Their relevance is confirmed by ongoing monitoring of epidemiological statistics and pharmacoeconomic aspects of Russian health care.
- All of our products have undergone strong quality, safety and efficacy control, and clinical and regulatory data from the countries where they are used have been thoroughly audited. Our selected drugs undergo pre-clinical and clinical trials in accordance with Russian and Eurasian protocols before they are commercialized.
- Most of our products are approved for use in children from infancy. The drugs are manufactured using the safest technology available.
QUALITY BY DESIGN
- We pay particular attention to quality during planning. Our production site is designed with the latest solutions and control systems to ensure consistent product quality.
- Our quality control laboratories are equipped with a wide range of sophisticated analytical instruments and tools.
- Our experienced and well-trained team of technical staff uses processes and systems developed in cooperation with industry-leading partners as well as local centers of expertise.
360-DEGREE QUALITY EMBEDMENT
- Our emphasis on quality cuts across the whole activity chain. We focus comprehensively on each distinct operational domain to ensure
360-degree quality coverage in accordance with cGMP, ISO and regulatory requirements. - We keep pace with advances in technology and use audits and benchmarks to ensure we comply with all emerging regulatory requirements and cGMP norms.
OWNERSHIP AT ALL LEVELS
- Our management takes full responsibility at the highest level to ensure that our quality management systems (QMS) are upgraded and
maintained, and quality objectives fulfilled at all times. - In addition to periodic internal reviews, we focus on regular training, awareness building and the enrichment of our employees, contractors,
suppliers and value-chain partners to achieve a coherent interconnected process for continuous improvement.
KNOW OUR PRODUCTS
VARICELLA VACCINE; (VAR-I-AID™)
A live attenuated viral vaccine consisting of Oka strain propagated on MRC-5 human diploid cells, presented in a sterile, lyophilised white to cream coloured cake form, which turns to white opalescent liquid after reconstitution indicated as a sub-cutaneous injection for active immunization for the prevention of varicella in individuals in the age group between 1-12 years. The internationally prescribed dosing regimen for this vaccine is:
• First dose at the age of 12-18 months;
• Second dose before 4 years, providing at least 3 months have elapsed since the first dose.
• Catch-up doses up to 12 years of age if not immunized earlier.
Each reconstituted vaccine contains in each single human dose of 0.5 ml:
• Not less than 1400 PFU of live attenuated varicella zoster virus (OKA Strain)
PRESENTATION:
• Mono carton of single dose vial of Varicella Vaccine
(Live), along with diluent
STORAGE CONDITION:
• Store at 2-8°C. Protect from light and avoid contact with disinfectant
• To be used immediately after reconstitution
ROTAVIRUS VACCINE; (ROTA-V-AID®)
A live attenuated (oral) pentavalent viral vaccine presented in a lyophilized form indicated for active immunization of healthy infants for the prevention of gastroenteritis due to rotavirus infection when administered orally as a 3-dose series.
Licensed from Serum Institute of India Ltd, the world’s largest vaccine producer, this vaccine has a WHO-PQ status and has several years of successful vaccination outcome spread across ~170 countries worldwide.
The internationally prescribed dosing regimen for this vaccine is:
• First dose at the age of 6 weeks;
• Second dose after 4 weeks from first dose; third dose
after 4 weeks from the second;
• In case of an incomplete dose (the baby spits up or regurgitates), a single replacement dose may bem administered during the same vaccination visit subject to physician’s advice.
• As per WHO recommendations, if the routine childhood immunizations are initiated later than 6 weeks of age and/or at a longer dose interval than 4-weeks, Rotavirus Vaccine, Live Attenuated (Oral) can still be administered, by itself or concomitantly with DTP, inactivated poliovirus vaccine (IPV), oral poliovirus vaccine (OPV), H. influenzae type b conjugate (Hib) vaccine, and hepatitis B vaccine. There are no restrictions on the infant’s consumption of food or liquid, including breast milk, either before or after vaccination with Rotavirus Vaccine, Live Attenuated (Oral).
Each reconstituted vaccine contains in each single human dose of 2.5 ml:
• Live, attenuated Bovine – Human Rotavirus Reassortant [G1, G2, G3, G4 and G9]* ≥ 105.6 FFU/Serotype (grown on
Vero Cells)
• Sterile Diluent (Citrate Bicarbonate Buffer) prepared using 9.6 mg/ml citric acid monohydrate and 25.6 mg/ml sodium bicarbonate
PRESENTATION:
• Single dose pack along with diluent
• 2 dose pack along with diluent
• Pack of 10 vials with diluent supplied separately
STORAGE CONDITION:
• Store at room temperature (up to 25°C).
• Protect from light and avoid contact with disinfectant
• To be used within 6 hours after reconstitution when stored at 2-8°C
HUMAN PAPILLOMAVIRUS VACCINE; (PAP-IV-AID™)
A sterile liquid quadrivalent vaccine which includes the recombinant major capsid (L1) protein of Human Papillomavirus Virus-Like Particles (HPV VLPs) of serotypes 6,11,16,18 produced by separate fermentations and self-assembled into VLPs which are further purified and adsorbed on aluminium-containing adjuvant. This vaccine is indicated for the prevention of cervical, vulvular and vaginal cancer, precancerous or dysplastic lesions, genital warts, persistent infection caused by Human Papillomavirus (HPV) Types 6, 11, 16, and 18) as well as to provide protection against HPV 31-, 33-, 52- and 58-related CIN (grades 1, 2,3) or AIS and offers a wide coverage of approximately 90% against papilloma virus prevalent across the world. The vaccine is licensed from the Serum Institute of India. The internationally prescribed dosing regimen for this vaccine is:
• For females and males aged 9 to 15 years and for females aged 16 to 26 years:
• Second dose: 1- 2 months after the first dose;
• Third dose: 4- 6 months after the first dose,
• Can be administered concomitantly (at a separate
injection site and in separate limbs) with Hepatitis B vaccine, Meningococcal vaccine, Diptheria vaccine, TDaP vaccine and Inactivated Polio vaccine (IPV)
Each single human dose of 0.5 ml sterile intramuscular
injection contains:
• Approx. 20 mcg of HPV 6 L1 protein, 40 mcg of HPV 11 L1 protein, 40 mcg of HPV 16 L1 protein, and 20 mcg of HPV 18 L1 protein
PRESENTATION:
• Single dose pack
• 2 dose pack
MENINGOCOCCAL VACCINE; (MENI-V-AID™)
A thermostable Pentavalent Meningococcal Conjugate Vaccine (A, C, Y, W-135, X) in lyophilized form conjugated with Tetanus toxoid and Diptheria CRM197 protein that offers the highest form of protection from all prevalent serotypes causing Meningococcal infection across the developed and developing nations. This vaccine has been licensed from the Serum institute of India who developed this product in collaboration with WHO and PATH.
The internationally prescribed dosing regimen for this vaccine is
• for children aged 9 months through 23 months, two doses administered 3 months apart; or
• for all children who did not receive Meningococcal vaccination as above, a first dose between 11 to 12 year age, followed by a booster at age 16 or provided at least 4 years have elapsed after the first dose.
• for individuals at higher risk of exposure to meningococcal disease, a single booster is recommended between age 2 through 55, subject to a 4-year time lapse between the previous meningococcal vaccination.
Each single human dose of 0.5 ml sterile intramuscular injection contains:
• Approx. 4 mcg each of serotype A, C, Y, W-135, X polysaccharides conjugated to Tetanus toxoid and Diptheria CRM 197 protein.
PRESENTATION:
• Single dose pack along with diluent
• Pack of 10 vials with diluent supplied separately
STORAGE CONDITION:
• Store at 2- 8 0C
• Excursion period – please refer packing insert
• Protect from light and avoid contact with disinfectant
MONOCLONAL ANTIBODY FOR RABIES ; (RAB-I-AID™)
This is a passive monoclonal antibody indicated as a postexposuren prophylaxis of rabies infection for individuals with suspected rabies exposure. If anatomically feasible, the full dose of this antibody should be thoroughly infiltrated in the area around and into the wounds. Any remaining volume should be injected intramuscularly at a site distant from the vaccine administration. The antibody must always be used in combination with rabies vaccine as part of post-exposure prophylaxis in line with the World Health Organization (WHO) recommendation.
The recommended dose of this Rabies antibody is:
• 3.33 IU/kg body weight
PRESENTATION:
• 100 IU/ 2.5 ml (40 IU/ml) vial
• 250 IU/2.5 ml (100 IU/ml) vial
MMR VACCINE (MEASLES, MUMPS, RUBELLA) (MMR-AID™)
A combination vaccine in lyophilised form administered as a subcutaneous injection for the active immunization against Measles, Mumps and Rubella in infants, children, adolescents and the young. This vaccine has been licensed from the Serum institute of India who is also the largest producer of this vaccine in the world.
Licensed from Serum Institute of India Ltd, the world’s largest vaccine producer, this vaccine has a WHO-PQ status and has several years of successful vaccination outcome spread across ~170 countries worldwide.
Each reconstituted vaccine contains in each single human dose of 0.5 ml:
• Not less than 1000 CCID50 of Measles virus
• Not less than 5000 CCID50 of Mumps virus
• Not less than 1000 CCID50 of Rubella virus
The internationally recognized dosing regimen for this vaccine is:
• First dose of MMR given in children – 12 months of age to 10 years of age;
• Second dose of MMR is advocated any time before the age of 6 years (elementary school entry 4-6 years) and thereafter Measles and Rubella vaccine is recommended.
PRESENTATION:
• Box of 10 single dose vials
• Box of 10 ampoules of 0.5 ml each, diluent provided
separately
STORAGE CONDITION:
• Store at 2-8°C.
• Excursion period of up to 72 hours in 20 – 25°C
• Protect from light and avoid contact with disinfectant
OUR FUTURE ROADMAP
Contact us on Email or on Phone:
Email – pv@pharmaid.com
Phone – +7 (495) 477-44-24 ext.15